DOI: 10.47102/annals-acadmedsg.2023308 ISSN: 0304-4602
Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia
Darintr Sosothikul, Chatphatai Moonla- General Medicine
Over the past decade, the development of emicizumab, the first-in-class factor VIII (FVIII), a mimetic monoclonal antibody bispecific to activated factor IX and factor X, has ushered in a significant revolution in non-factor replacement therapy for patients with congenital FVIII deficiency or haemophilia A (HA).